Your Health, We Care
Neratinib is indicated as a monotherapy for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast cancer, following adjuvant therapy based on trastuzumab.
Neratinib in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received two or more anti-HER2-based treatment regimens in the metastatic setting.
FDA，2021.06
It is indicated for the treatment of early-stage and advanced-stage HER2-positive breast cancer, and can be used as a monotherapy for adjuvant treatment or in combination with cape···【more】
Article source：Lucius LaosRelease date：2026-01-05Recommended：0
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
